Toxicology

Algenesis Unveils Groundbreaking Biodegradable TPU Material, Pioneering a Future Without Microplastics

Retrieved on: 
Thursday, March 21, 2024
Research, Health, Microplastics, Toxicology, Scientific Reports, Nutrient, Environment, Recycling, UCSD, Partnership, SAN, UC, Trelleborg, Mortality, Bacteria, University, TPU, Nature, Carbon, Shoe, Plastic, Microbiology, Petroleum, Soil, Agriculture

These findings point to an urgent need to remove existing microplastics from the environment, while simultaneously adopting sustainable materials that do not produce these persistent microplastics.

Key Points: 
  • These findings point to an urgent need to remove existing microplastics from the environment, while simultaneously adopting sustainable materials that do not produce these persistent microplastics.
  • Algenesis' latest breakthrough is the development of a bio-based TPU that directly addresses the microplastics crisis thanks to its biodegradability.
  • Algenesis demonstrated in its study that tiny plastic particles from this new TPU are able to rapidly biodegrade under home composting conditions.
  • Algenesis' biodegradable TPU material represents a major leap forward in reducing the production and accumulation of microplastics, thus safeguarding our ecosystems and human health.

A paper showing that exposure to fragrance ingredients is extremely low wins coveted Society of Toxicology award

Retrieved on: 
Tuesday, March 19, 2024
Crème, DST, Top Ten, Science, TTC, SOT, Running, Risk assessment, Mentorship, Abstract, Commercial director, Skin, Toxicology, Research institute

SALT LAKE CITY, March 19, 2024 /PRNewswire/ -- A collaborative poster presentation on fragrance ingredient exposure by The Research Institute for Fragrance Materials, Inc. (RIFM.org) and scientific modeling and data analytics company Creme Global (cremeglobal.com) earned its presenters a prestigious Top Ten Presentation Award during the Risk Session of SOT's 63rd Annual Meeting and ToxExpo, held in Salt Lake City, Utah, March 10-14th, 2024. Some 300 abstracts were in the running.

Key Points: 
  • I'm proud of how expertly RIFM's scientists communicate our critical fragrance safety science to other scientists."
  • "And it was especially rewarding to receive the Risk Assessment Specialty Section Top Ten Abstract Award for our low-exposure paper."
  • The study authors compared the fragrance exposure of the highest-end product users to the internationally recognized Threshold of Toxicological Concern (TTC) and Dermal Sensitization Threshold (DST) to determine a realistic understanding of consumer exposure to fragrance.
  • "RIFM has set the gold standard in ingredient risk assessment, gathering and sharing real usage data."

Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder

Retrieved on: 
Thursday, March 14, 2024
Patient, Public, OUD, Research, Columbia University, Opioid use disorder, IND, GMP, Report, Ibogaine, Toxicology, Pharmaceutical industry

NEW YORK, March 14, 2024 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for mental health disorders, today announced that it has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders. As summarized in a recent New York Times article (Powerful Psychedelic Gains Renewed Attention as a Treatment for Opioid Addiction), ibogaine, a plant-derived psychoactive compound, has accumulated data from trials and case reports that point to its robust efficacy as a treatment for substance use disorders. However, the development of ibogaine as a pharmaceutical has long been hindered by its significant cardiovascular toxicity.

Key Points: 
  • However, the development of ibogaine as a pharmaceutical has long been hindered by its significant cardiovascular toxicity.
  • This grant provides non-dilutive funding to support IND-enabling toxicology studies, GMP manufacturing, and Phase 1/1b clinical trials in healthy volunteers and opioid use disorder (OUD) patients for GM-3009.
  • The planned clinical work will seek to confirm that GM-3009 eliminates the cardiovascular risks associated with ibogaine and demonstrate proof-of-concept efficacy in attenuating symptoms associated with OUD.
  • As Gilgamesh moves forward with its clinical trials, the company is poised to lead a new era in addiction treatment, marked by safer, more effective, and scientifically validated therapies.

Environmental Risk and Compliance Strategy Expert Tapped for Leadership at J.S. Held

Retrieved on: 
Wednesday, March 13, 2024
Health, EH&S, Forward, Risk, Suspension, Environment, Biophysical environment, Pass, ESG, EH, Epidemiology, EPA, Fossil fuel, Safety, Toxicology, Superfund, Crosscurrents, EHS, Management

Held, proudly celebrating 50 transformative years, elevates Executive Vice President John Peiserich, Esq ., to oversee the Environmental, Health & Safety (EHS) practice.

Key Points: 
  • Held, proudly celebrating 50 transformative years, elevates Executive Vice President John Peiserich, Esq ., to oversee the Environmental, Health & Safety (EHS) practice.
  • Held environmental risk and compliance strategy experts, John holds a J.D.
  • "John's background as a practicing environmental attorney best positions John to understand, anticipate, and discuss with counsel the ever-changing legal landscape surrounding environmental risk and compliance strategy," observes Paul Banks.
  • John has extensive experience evaluating the risk associated with potential and ongoing compliance obligations, developing strategies around those obligations, and working to implement a client-focused compliance strategy.

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 11, 2024
Research, GDF15, PSC, Part, Vomiting, Pregnancy, MSS, Liver, Atlas, Preterm birth, NGM, LAIR1, Nausea, Hospital, ILT3, GFRAL, Food and Drug Administration, NASH, Therapy, Woman, Toxicology, Liver disease, CRC, Cirrhosis, Biomarker, Place of birth, Colorectal cancer, Agreement, Acquisition, Plan, FGF19, AASLD, FDA, Food, Weight loss, Primary sclerosing cholangitis, Pembrolizumab, Dehydration, Bile, Hyperemesis gravidarum, HG, Patient, Pre-eclampsia, Malnutrition, Pharmaceutical industry

--On February 26, 2024, announced that it had entered into the Agreement and Plan of Merger with Atlas Neon Parent, Inc., and Atlas Neon Merger Sub, Inc.--

Key Points: 
  • The combination of NGM707 and pembrolizumab was generally well-tolerated at all four doses (200, 600, 1200, 1800 mg) of NGM707.
  • Additional details can be found in NGM Bio’s recent filings with the United States Securities and Exchange Commission (SEC).
  • NGM Bio anticipates that the Offer and the Merger contemplated under the Merger Agreement will be consummated in the second quarter of 2024.
  • If the Merger is effected, NGM Bio’s common stock will be delisted from The Nasdaq Stock Market LLC and NGM Bio will be privately held.

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

Retrieved on: 
Wednesday, February 28, 2024
Therapy, Anxiety, Toxicology, New Drug Application, Data analysis, Absorption, FDA, GLP, Safety, Administration, Post-traumatic stress disorder, SILO, PTSD, IND, Pharmaceutical industry

SARASOTA, FL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive results from its non-GLP small animal dose-ranging study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD).

Key Points: 
  • The purpose of the non-GLP small animal study was to identify the maximum tolerated intranasal dose of the drug pharmacokinetic and determine the therapeutically relevant dose range to be studied in clinical trials.
  • Data analysis demonstrated rapid absorption of SPC-15 with good exposure over a 24-hour period, suggesting a once-per-day human intranasal dosing regimen would be optimal.
  • “Non-GLP and GLP toxicology and safety pharmacology studies are required steps before seeking approval for our first-in-human clinical-stage trials of SPC-15,” said Eric Weisblum, CEO of Silo.
  • This is an exciting step forward for our Company as we advance our lead therapeutic, SPC-15.”

Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases

Retrieved on: 
Tuesday, February 27, 2024
Investigational New Drug, Toxicology, Acne, Toxicity, Atopic dermatitis, Drug development, Skin, Risk, GLP, Safety, Human, Rosacea, IND, Pharmaceutical industry

Toxicology studies are an essential part of drug development as they help to evaluate the potential safety and toxicity of a drug candidate before it is tested on humans.

Key Points: 
  • Toxicology studies are an essential part of drug development as they help to evaluate the potential safety and toxicity of a drug candidate before it is tested on humans.
  • There is a real need for skin disease drugs that offer high efficacy and a low risk of adverse effects with long-term use.
  • For conditions like AD, an inflammatory skin disease that affects up to 25% of babies and young children, there is a need for safer treatment options.
  • DB-007-4 is a topical multi-disease treatment that targets important pathways that play a vital role in the development of inflammatory skin diseases while being well-tolerated by skin.

Philip Morris International Inc. Declares Regular Quarterly Dividend of $1.30 Per Share

Retrieved on: 
Thursday, March 7, 2024
Tobacco, Retail, Smoke, Toxicology, ZYN, Food, Sale, Philip Morris International, Life, PMI, IQOS, Research

The Board of Directors of Philip Morris International Inc. (NYSE: PM) today declared a regular quarterly dividend of $1.30 per common share, payable on April 9, 2024, to shareholders of record as of March 21, 2024.

Key Points: 
  • The Board of Directors of Philip Morris International Inc. (NYSE: PM) today declared a regular quarterly dividend of $1.30 per common share, payable on April 9, 2024, to shareholders of record as of March 21, 2024.
  • For more details on stock, dividends and other information, see www.pmi.com/dividend .
  • Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector.
  • The company’s current product portfolio primarily consists of cigarettes and smoke-free products.

The Access to Advanced Health Institute Receives up to $12.7 Million to Develop Novel NanoAlum Adjuvant Formulation for Better Protection Against Tuberculosis and Pandemic Influenza

Retrieved on: 
Thursday, March 7, 2024
COVID-19, Research, Clinical Trials, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Hepatitis A, Senior, Infectious Disease Research Institute, Immune system, Toxicology, Doctor of Philosophy, Medicine, Multimedia, TLR, Government, Infection, Access, Defense, RTS, Vaccine, Notifiable disease, Shingles, Malaria, Unitary state, Respiratory syncytial virus, Formulation, Fungus, MPH, MCDC, Disease, Tuberculosis, OTA, Parasitism, HIV, Cancer

View the full release here: https://www.businesswire.com/news/home/20240307661956/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240307661956/en/
    This five-year prototype project will support AAHI’s development and optimization of “NanoAlum” – a novel nanoparticle adjuvant formulation, made from aluminum salts (“alum”).
  • Alum-adjuvanted vaccines have been less effective against diseases such as tuberculosis and influenza, which are more complex to target and can be challenging to manufacture because they require special sterilization methods.
  • AAHI’s NanoAlum formulation changes the size, shape, and charge of alum particles to enhance specific immune responses for better vaccine protection against complex diseases.
  • AAHI’s prototype project for MCDC will pair the combined 3M-052 and NanoAlum formulation with tuberculosis and pandemic influenza vaccine antigens.

Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Development

Retrieved on: 
Monday, March 4, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Inhalation, Toxicology, Cough, Pain, Eye, Chronic cough, Venture round, Therapy, Patient, Knowledge, Disease, Itch, Pharmaceutical industry

Nocion Therapeutics, a clinical-stage biopharmaceutical company, today announced that it has raised $62 million in Series B funding.

Key Points: 
  • Nocion Therapeutics, a clinical-stage biopharmaceutical company, today announced that it has raised $62 million in Series B funding.
  • Proceeds from the financing will be used to evaluate the lead program, Taplucanium Dry Powder for Inhalation, in a Phase 2b study in Chronic Cough patients.
  • With this financing, Nocion has raised $122 million since the company was founded in 2018.
  • “We are grateful to our new and existing investors for their commitment to our lead program in this challenging disease,” said Dr. Richard Batycky, Chief Executive Officer of Nocion.